ESSANTIA Trademark

Trademark Overview


On Monday, July 10, 2017, a trademark application was filed for ESSANTIA with the United States Patent and Trademark Office. The USPTO has given the ESSANTIA trademark a serial number of 87521932. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 8, 2021. This trademark is owned by Allergan Finance, LLC. The ESSANTIA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations...
essantia

General Information


Serial Number87521932
Word MarkESSANTIA
Filing DateMonday, July 10, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 8, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 5, 2017

Trademark Statements


Goods and ServicesPharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical blood therapy preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, medicated toners, medicated moisturizers, medicated rejuvenators, medicated rehydrating creams, and medicated lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, July 15, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Finance, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Party NameAllergan Finance, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Monday, March 8, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 8, 2021ABANDONMENT - NO USE STATEMENT FILED
Thursday, August 13, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 12, 2020EXTENSION 5 GRANTED
Friday, July 24, 2020EXTENSION 5 FILED
Wednesday, August 12, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, July 24, 2020TEAS EXTENSION RECEIVED
Tuesday, January 28, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 24, 2020EXTENSION 4 GRANTED
Friday, January 24, 2020EXTENSION 4 FILED
Friday, January 24, 2020TEAS EXTENSION RECEIVED
Monday, July 8, 2019ASSIGNED TO EXAMINER
Tuesday, June 18, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 14, 2019EXTENSION 3 GRANTED
Friday, June 14, 2019EXTENSION 3 FILED
Friday, June 14, 2019TEAS EXTENSION RECEIVED
Friday, January 25, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 23, 2019EXTENSION 2 GRANTED
Wednesday, January 23, 2019EXTENSION 2 FILED
Wednesday, January 23, 2019TEAS EXTENSION RECEIVED
Saturday, July 21, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 19, 2018EXTENSION 1 GRANTED
Thursday, July 19, 2018EXTENSION 1 FILED
Thursday, July 19, 2018TEAS EXTENSION RECEIVED
Tuesday, January 30, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 5, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 5, 2017PUBLISHED FOR OPPOSITION
Wednesday, November 15, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, October 30, 2017ASSIGNED TO LIE
Friday, October 13, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, October 13, 2017EXAMINER'S AMENDMENT ENTERED
Friday, October 13, 2017NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, October 13, 2017EXAMINERS AMENDMENT E-MAILED
Friday, October 13, 2017EXAMINERS AMENDMENT -WRITTEN
Thursday, October 5, 2017ASSIGNED TO EXAMINER
Saturday, July 15, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, July 13, 2017NEW APPLICATION ENTERED IN TRAM